PDA
Taken as a BPC-157 substitute
Pentadeca arginate
Match every finding to its exact substance, formulation, route and study population. A related molecule or approved medicine does not validate a catalog vial.
Structure not independently published
At a glance
Why people take it. And what backs it up.
-
Heal injuries faster
People report it, not studied
Clinics that switched from BPC-157 give daily shots near tendon, muscle and joint injuries, hoping to speed healing.
Sources (3)
-
“500 mcg subcutaneous injections once daily close to site of injury”
-
ClinicWittmer Rejuvenation Clinic: PDA treatment plan (opens in a new tab)
“Pentadeca Arginate Peptide (PDA) Treatment Plan for Injury Recovery & Tissue Repair”
-
“Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptide.”
-
-
Heal the gut
People report it, not studied
Clinics and pharmacies sell capsules for gut problems such as ‘leaky gut’, IBS and reflux, borrowing claims made for BPC-157.
Sources (2)
-
ClinicEnhanced Wellness (New York clinic): PDA patient handout (2025) (opens in a new tab)
“PDA may help to reduce leaky gut syndrome by strengthening the gut barrier and reducing intestinal permeability.”
-
“Patients with: Leaky Gut Syndrome, IBS, IBD (Crohn’s, Ulcerative Colitis), acid reflux, stomach ulcers, or general digestive inflammation.”
-
-
Replace BPC-157
People report it, not studied
Many clinics offer it because US pharmacies stopped compounding BPC-157, presenting it as a more stable version; its exact identity is unverified.
Sources (3)
-
PodcastHuberman Lab podcast with Dr. Craig Koniver (transcript) (opens in a new tab)
“not BPC anymore, but Pentadeca Arginate instead, because you can’t get BPC-157 compounded”
-
“Pentadeca Arginate, abbreviated PDA and sometimes written pentadecapeptide arginate, is marketed as an improved and more stable form of BPC-157.”
-
ClinicPRAMAH / The Haven (Tampa clinic): page title (opens in a new tab)
“New BPC (Pentadeca Arginate Complex)”
-
Evidence briefing
Verification gapWhat the sources support.
Unavailable: no primary-source definition or study was found for the seller label “PDA.” FDA’s BPC-157 review covers BPC-157 free base and acetate, but does not establish PDA as that salt, a distinct molecule or a stabilized form.
Exact identity, salt stoichiometry, sequence, approval status and route remain unverified; BPC-157 literature cannot be assigned to PDA by name alone.
The research. What’s been studied.
Clinical benefit unverified
-
Marketed tissue-repair claims
Some sellers claim effects similar to BPC-157, but no primary study of the sold PDA product was identified.
-
Human evidence
No primary-source human study of a clearly defined PDA substance was identified.
What do these labels mean?
- Human evidence: approved-drug data or larger human studies, within the populations and uses studied.
- Early human studies: small, preliminary or limited human studies.
- Animal & lab studies: animal or laboratory findings that do not establish effects in people.
- Unverified: a proposed use or claim without verified supporting clinical evidence.
How each claim was reviewed (3)
Reported effects and evidence.
A citation may support, qualify or correct a claim. Read the study scope; a laboratory result is not an established benefit in people. Each review covers a claim as it was first collected; the tiles above show the collection’s current wording.
-
Unknown — no direct primary source verified. Attributed marketing claim; exact identity/evidence unresolved
Review of “Tissue repair”
PDA is marketed for tissue repair; no direct compound-specific efficacy source was verified.
Limitations and applicability. No compound-specific primary source verified. Do not inherit BPC-157 results across a changed molecule/form.
Unknown: no direct primary source verified. This does not mean that no research exists.
Original collected claim and review history
Original title: Tissue repair
Marketed to support tendon, ligament and muscle healing like BPC-157.
Original label: claimed. Preserved for traceability; the reviewed wording above qualifies this record.
Record pda:benefit:1 · Annotated 2026-10-01 · Review method
-
Unknown — no direct primary source verified. Extrapolated marketing claim
Review of “Gut healing”
PDA gut-healing claims are extrapolated from BPC-157 research; direct PDA evidence remains unverified.
Limitations and applicability. BPC-157 rodent data cannot validate PDA or a human gut-healing claim.
Unknown: no direct primary source verified. This does not mean that no research exists.
Original collected claim and review history
Original title: Gut healing
Claimed to support the gut lining, based on BPC-157’s animal research.
Original label: claimed. Preserved for traceability; the reviewed wording above qualifies this record.
Record pda:benefit:2 · Annotated 2026-10-01 · Review method
-
Unknown — no direct primary source verified. Stability comparison unresolved
Review of “More stable form”
PDA is marketed as more stable; no direct comparative stability study was verified in this review.
Limitations and applicability. A stability advantage requires analytical comparison of exact identities and conditions. Absence of search results is not proof no study exists.
Unknown: no direct primary source verified. This does not mean that no research exists.
Original collected claim and review history
Original title: More stable form
Sold as a more stable version of BPC-157. No published studies test PDA itself.
Original label: claimed. Preserved for traceability; the reviewed wording above qualifies this record.
Record pda:benefit:3 · Annotated 2026-10-01 · Review method
The research in detail
Evidence category
Little or no published research
No product-specific primary clinical or preclinical study of PDA was identified. Its marketed claims should not be treated as BPC-157 evidence.
Evidence is assessed claim by claim above. Regulatory approval, study design, findings and relevance are separate questions; there is no single evidence score.
Risks and unknowns. What to know first.
Collected cautions follow. These are not an exhaustive or independently validated safety assessment; claim references do not automatically support every caution.
- Unknown.
What people report
-
Study
There is essentially no independent published human research on PDA; claims rely on BPC-157 animal studies.
Published dosing records. No established dose.
Historical label and trial records for the named product, route, population and indication. These records are not a personal schedule or a validated regimen for a catalog vial. Source attribution does not establish applicability.
PDA (“pentadeca arginate”) is marketed as a salt form of BPC-157. PubMed and ClinicalTrials.gov list no study of it under any of its names, and BPC-157 itself has no established human dose.
Any dose you see online for it is a guess, not a tested dose.
Community protocols. Reported online. Not clinically validated.
Community reports Collection date: 30 Sep 2026Clinics that switched from BPC-157 to PDA mostly give 500 mcg once a day by injection under the skin (range 250–500 mcg), or 500–1,000 mcg capsules by mouth.
More about this
The numbers are carried over from BPC-157, and there are no PDA-specific human studies.
Daily injection (clinic standard)
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Clinic: Wittmer Rejuvenation Clinic, PDA treatment plan
- Clinic: Enhanced Wellness (New York clinic), PDA patient handout (2025)
- Podcast: Huberman Lab podcast with Dr. Craig Koniver (transcript)
- Clinic: PRAMAH / The Haven (Tampa clinic), ‘New BPC – Pentadeca Arginate Complex’
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 500 mcg (some start at 250 mcg)
- How often
- Once a day, usually in the morning; one clinic gives it Monday to Friday only
- Route
- Injection under the skin, near the injury or in the belly
- Timing
- Morning. One clinic says it does not need an empty stomach.
- How long
- One clinic runs it for 12 weeks straight; a 15 mg vial lasts about a month
- Cycle
- One clinic: 12 weeks on, then an 8-week break. Another: 5 days on, 2 days off.
- Ramp
- Some start at 250 mcg and use 500 mcg as the standard dose
- Mixing
- 15 mg vial + 7.5 mL bacteriostatic or sterile water (2 mg per mL); 25 units (0.25 mL) = 500 mcg
- The same ‘15 mg vial, 7.5 mL, 25 units once daily’ instruction appears at more than one clinic, which suggests a shared pharmacy protocol.
- Dr. Craig Koniver presented PDA on the Huberman Lab podcast as a doctor-prescribed stand-in for BPC-157 after US pharmacies stopped compounding it.
Sources (4)
-
ClinicWittmer Rejuvenation Clinic, PDA treatment plan (opens in a new tab)
“Dosage: Inject 25 units (500mcg) subcutaneously daily in the morning”
-
ClinicEnhanced Wellness (New York clinic), PDA patient handout (2025) (opens in a new tab)
“Reconstitute the vial with 7.5mL of sterile water for injection. Administer 25 units subcutaneously once daily.”
-
PodcastHuberman Lab podcast with Dr. Craig Koniver (transcript) (opens in a new tab)
“We’re using 500 micrograms injected daily. Again, we like Monday through Friday. Take the weekends off.”
-
ClinicPRAMAH / The Haven (Tampa clinic), ‘New BPC – Pentadeca Arginate Complex’ (opens in a new tab)
“500 mcg subcutaneous injections once daily close to site of injury”
By mouth (capsules)
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
- Clinic: PRAMAH / The Haven (Tampa clinic), ‘New BPC – Pentadeca Arginate Complex’
- Clinic: Enhanced Wellness (New York clinic), PDA patient handout (2025)
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 500–1,000 mcg
- How often
- Once a day
- Route
- By mouth
- Used for gut complaints, as with swallowed BPC-157. Clinics sell 100, 500 and 1,000 mcg capsules.
Sources (2)
-
ClinicPRAMAH / The Haven (Tampa clinic), ‘New BPC – Pentadeca Arginate Complex’ (opens in a new tab)
“500 mcg capsules once daily”
-
ClinicEnhanced Wellness (New York clinic), PDA patient handout (2025) (opens in a new tab)
“For oral administration, we offer 500 mcg and 1,000 mcg capsules.”
Show all 4 protocolsShow fewer protocols
Nasal spray
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 1–2 sprays of a 0.2 mg per mL spray in each nostril
- How often
- 1–2 times a day
- Route
- Nasal spray
- Only one clinic found offering this.
Sources (1)
-
ClinicPRAMAH / The Haven (Tampa clinic), ‘New BPC – Pentadeca Arginate Complex’ (opens in a new tab)
“1-2 sprays each nostril 1-2 times daily”
Skin cream
Collected report · exact form and route are only as reported below. Source date and reporter identity are not separately verified. Collection checked 30 Sep 2026; presentation annotated 2026-10-01.
Frequency labels describe this collection, not a measured population. Contradictory records remain available.
Details and sourcesHide details
- Dose
- 1–2 clicks of an 800 mcg per mL cream
- How often
- Once a day
- Route
- Topical (on the affected area)
- Only one clinic found offering this.
Sources (1)
-
ClinicPRAMAH / The Haven (Tampa clinic), ‘New BPC – Pentadeca Arginate Complex’ (opens in a new tab)
“1-2 clicks of cream to affected area daily”
Where the numbers come from
PDA spread through US clinics in 2024–2025 as a replacement after FDA blocked pharmacy compounding of BPC-157 in 2023. Its doses (250–500 mcg injected, 500–1,000 mcg swallowed) are copied from BPC-157 protocols. A clinician-training site says there is no independent published human research on PDA itself.
Research notes
What PDA is chemically is described inconsistently. A clinician-training site says it is BPC-157 made as an arginate salt with the same 15-amino-acid sequence. On the Huberman Lab podcast, Dr. Koniver described it both as swapping acetate for arginate and as a one-amino-acid substitution. If it is simply a BPC-157 salt, BPC-157’s regulatory problems (FDA compounding restrictions, the World Anti-Doping Agency sport ban) may apply to it too; no regulator has addressed PDA by name. No PDA-specific side-effect reports were found (see the BPC-157 entry for problems reported with the parent peptide). Almost all sources are clinics; on Reddit a self-described prescriber says they prefer the arginate salt for swallowed BPC-157, and there is little forum dosing discussion specific to PDA.
What it is. In plain English.
A product marketed as PDA or pentadeca arginate whose exact identity and relationship to BPC-157 could not be verified from primary sources.
PDA is a seller name expanded as “pentadeca arginate.” The exact sequence, salt composition and relationship to BPC-157 could not be verified from a product-specific primary source.
No direct research was found to establish a distinct mechanism or clinical effect for the product sold as PDA. BPC-157 findings cannot be assumed to apply.
Reviewed 2026-10-01.
Structure. Nothing to show yet.
No experimental 3D structure of pentadeca arginate (PDA) is in the .
Its chemical structure isn’t published (this site lists its sequence as unknown), so there is nothing to search by. If it turns out to be BPC-157 as an arginine salt, that peptide has no entry either.
Checked 30 Sep 2026.
Specs. The facts at a glance.
- Length
- 15 amino acids (claimed)
- Sold as
- PDA 10 mg
- Regulatory status
- Identity and regulatory status unverified. No approval or human clinical evidence was identified for a clearly defined product sold as PDA.
- Also known as
- Pentadeca arginate
Sources. What this page rests on.
Every source behind this page, with what it says and when it was checked, is in the Source library.
Original overview and research notes · annotated 2026-10-01
Historical collection text. Read alongside the claim corrections above; identity or evidence qualifications may supersede this wording.
BPC-157 alternative for tissue repair
A newer BPC-157 alternative with almost no published research of its own.
“Pentadeca” means fifteen. It’s marketed as a stabilized form of BPC-157, usually described as the same 15-amino-acid sequence prepared as an arginine salt. Compounding pharmacies began offering it after BPC-157 was restricted.
Claimed to work like BPC-157: tissue repair, and gut healing.
Essentially no peer-reviewed studies on PDA itself. Its reputation borrows from BPC-157’s animal research.
Original status record: Not approved. Regulatory standing unsettled.